Strategies to Mitigate the Toxicity of Cancer Therapeutics

1st Edition, Volume 155 - June 30, 2022
Editors: David A. Gewirtz, Paul B. Fisher
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 9 0 0 8 7 - 4
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 9 0 0 8 8 - 1

Strategies to Mitigate the Toxicity of Cancer Therapeutics, Volume 155 in the Advances in Cancer Research series, highlights new advances in the field, with this new volume presen… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Strategies to Mitigate the Toxicity of Cancer Therapeutics, Volume 155 in the Advances in Cancer Research series, highlights new advances in the field, with this new volume presenting interesting chapters, each of which is written by an international board of authors.

Cover image
Title page
Table of Contents
Copyright
Contributors
Preface
Chapter One: An overview of chemotoxicity and radiation toxicity in cancer therapy
Abstract
1: Introduction
2: Cardiotoxicity
3: Pulmonary toxicity
4: Renal toxicity
5: Gastrointestinal toxicity
6: Neuromuscular toxicity
7: Cognitive dysfunction associated with chemotherapy: “Chemobrain or chemo fog”
8: Myalgias and arthralgias
9: Cutaneous toxicity
10: Secondary malignancies
11: Side effects of immune checkpoint inhibitors
12: Radiation therapy
13: Mitigating/circumventing chemotoxicity
14: Conclusion
References
Chapter Two: Chemobrain: A review on mechanistic insight, targets and treatments
Abstract
1: Introduction
2: Impact of chemobrain in patients
3: Symptoms and epidemiology
4: Mechanisms contributing to chemobrain
5: Targets and treatment options
6: Current status and personalized therapy
7: Future perspectives
8: Conclusion
Reference
Further reading
Chapter Three: Nephrotoxicity in cancer treatment: An update
Abstract
1: Introduction
2: Risk factors for renal toxicities in cancer therapy
3: Nephrotoxicity of chemotherapeutic agents and management
4: Renoprotective effects of some novel anticancer therapeutics
5: Conclusions
References
Chapter Four: Chemotherapy induced gastrointestinal toxicities
Abstract
1: Introduction
2: Chemotherapy-induced diarrhea
3: Chemotherapy-induced mucositis (CIM)
4: Emerging mechanisms underlying chemotherapy-induced gastrointestinal toxicity
5: Treatment of CID
6: The gut and chemotherapy-induced peripheral neuropathy
7: Conclusion
References
Chapter Five: Cardiac complications of cancer therapies
Abstract
1: Introduction
2: Cancer therapeutic agents
3: Current and promising therapies to prevent chemotherapy-induced cardiotoxicity
4: Conclusions
Acknowledgments
References
Chapter Six: Strategies to mitigate the toxicity of cancer therapeutics
Abstract
1: Overview of organ specific toxicities
2: Cancer related cognitive impairment
3: Ocular toxicities
4: Ototoxicity
5: Oral mucosal toxicities
6: Gastrointestinal toxicities
7: Renal toxicity
8: Aromatase inhibitor-associated musculoskeletal syndrome
9: Chemotherapy induced peripheral neuropathy (CIPN)
10: Immunotherapy-induced autoimmunity
11: Putting it all together. What is the future of symptom science?
References

David A. Gewirtz

Dr. Gewirtz received his PhD degree from Mt. Sinai School of Medicine of the City University of New York. He has been at Virginia Commonwealth University in the Department of Pharmacology and Toxicology and as a member of the Massey Cancer Center for his entire career. His work has been in the areas of cancer chemotherapy and radiotherapy, originally in breast cancer, but more recently extending to lung cancer, prostate cancer and head and neck cancer. His interests have long been in the nature of alternative tumor responses to therapy, most prominently autophagy and senescence. He has long argued that senescence is not an irreversible form of growth arrest, that senescence could represent one form of tumor dormancy and furthermore that recovery from senescence could contribute to disease recurrence. His most recent publication describes the impact of the senolytic agent, ABT-263 (navitoclax) on breast and lung tumor cells induced into senescence by cancer chemotherapy and radiation.

Affiliations and expertise

Department of Pharmacology and Toxicology, Virginia Commonwealth University; Member of the Massey Cancer Center, VA, USA

Paul B. Fisher

Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).

Affiliations and expertise

Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, USA